Bringing the fundamentals into focus…
Back to Telix Pharmaceuticals Limited
How Telix Pharmaceuticals Limited stacks up
TLX · against 334 other Healthcare companies of similar size
Valuation
31/ 100
Below the middle of the pack.
Ranked #243 of 335 · scores higher than 27% of peers
Bars: peers in each 10-point band of the valuation score30 peers with a valuation score of 30–39, including TLX · Click a bar to see the companies
Why valuation scores 31?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield, which is weaker than most Healthcare peers.
- less operating profit (EBITDA) for the company's total value: weaker than 61% of peers. EBITDA yield: 0.8% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -0.1% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -0.7% vs peer median 0.0%
Metric by metric
Position: dot = TLX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | TLX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 329 reported | 1.1% | 2.3% | 44% | 30% | |
| EBITDA yieldHigher is better · 329 reported | 2.1% | 4.7% | 34% | 50% | |
| Free cash flow yieldHigher is better · 174 reported | Not reported | -0.2% | — | — | 20% |
| Book yieldHigher is better · 327 reported | 15.9% | 29.6% | 26% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around TLX| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 235 | 3.3B USD | 33 | 39 | |
| 241 | 1.5B EUR (≈$1.6B) | 32 | 44 | |
| 241 | 3.0B CHF (≈$3.5B) | 32 | 33 | |
| 243 | 2.2B USD | 31 | 36 | |
| 243 | 3.1B USD | 31 | 46 | |
| 245 | 2.21T KRW (≈$1.6B) | 30 | 57 | |
| 245 | 4.2B USD | 30 | 41 | |
| 245 | 2.6B AUD (≈$1.7B) | 30 | 62 | |
| 245 | 4.7B USD | 30 | 42 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score